Enzyme kinetic study of a new cardioprotective agent, KR-32570 using human liver microsomes and recombinant CYP isoforms

Archives of Pharmacal Research

Volumn 30, Issue 4, 2007, Pages 469-474

  Kim, Hyojin ^b   Seo, Kyung Ah ^b   Kim, Hyunmi ^b   Hye, Suk Lee ^c   Lee, Choong Hwan ^d   Shin, Jae Gook ^b   Liu, Kwang Hyeon ^a,b  

^a Inje University   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Wonkwang University   (South Korea)

^d Konkuk University   (South Korea)

Author keywords

Enzyme kinetics; KR 32570; LC MS MS; Microsomes

Indexed keywords

EID: 34248167561     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02980221     Document Type: Article

References (18)

1. Andersson, T., Miners, J. O., Veronese, M. E., and Birkett, D. J., Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br. J. Clin. Pharmacol., 38, 131-137 (1994).
2. Baumgarth, M., Beier, N., and Gericke, R., (2-Methyl-5-(methylsulfonyl) benzoyl)guanidine Na+/H+ antiporter inhibitors. J. Med. Chem., 40, 2017-2034 (1997).
3. Ekins, S., Ring, B. J., Binkley, S. N., Hall, S. D., and Wrighton, S. A., Autoactivation and activation of the cytochrome P450s. Int. J. Clin. Pharmacol. Ther., 36, 642-651 (1998).
4. Guzman-Perez, A., Wester, R. T., Allen, M. C., Brown, J. A., Buchholz, A. R., Cook, E. R., Day, W. W., Hamanaka, E. S., Kennedy, S. P., Knight, D. R., Kowalczyk, P. J., Marala, R. B., Mularski, C. J., Novomisle, W. A., Ruggeri, R. B., Tracey, W. R., and Hill, R. J., Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility. Bioorg. Med. Chem. Lett, 11, 803-807 (2001).
5. Karmazyn, M., Gan, X. T., Humphreys, R. A., Yoshida, H., and Kusumoto, K., The myocardial Na(+)-H(+) exchange: structure, regulation, and its role in heart disease. Circ Res., 85, 777-786 (1999).
6. Kenworthy, K. E., Clarke, S. E., Andrews, J., and Houston, J. B., Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos, 29, 1644-1651 (2001).
7. Kim, H., Kang, S., Kim, H., Yoon, Y. J., Cha, E. Y., Lee, H. S., Kim, J. H., Yea, S. S., Lee, S. S., Shin, J. G., and Liu, K. H., In vitro metabolism of a new cardioprotective agent, KR-32570, in human liver microsomes. Rapid. Commun. Mass. Spectrom., 20, 837-843 (2006).
8. Kim, M. J., Moon, C. H., Kim, M. Y., Lee, S., Yi, K. Y., Yoo, S. E., Lee, S. H., Baik, E. J., and Jung, Y. S., KR-32570, a novel Na+/H+ exchanger-1 inhibitor, attenuates hypoxia-induced cell death through inhibition of intracellular Ca2+ overload and mitochondrial death pathway in H9c2 cells. Eur. J. Pharmacol., 525, 1-7 (2005).
9. Lee, B. H., Yi, K. Y., Lee, S., Lee, S., and Yoo, S. E., Effects of KR-32570, a new sodium hydrogen exchanger inhibitor, on myocardial infarction and arrhythmias induced by ischemia and reperfusion. Eur. J. Pharmacol., 523, 101-108 (2005a).
10. Lee, S., Yi, K. Y., Hwang, S. K., Lee, B. H., Yoo, S. E., and Lee, K., (5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. J. Med. Chem., 48, 2882-2891 (2005b).
11. Lin, Y., Lu, P., Tang, C., Mei, Q., Sandig, G., Rodrigues, A. D., Rushmore, T. H., and Shou, M., Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug. Metab. Dispos., 29, 368-374 (2001).
12. Rodrigues, A. D., Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem. Pharmacol., 57, 465-480 (1999).
13. Schrag, M. L. and Wienkers, L. C., Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Adv Exp Med Biol., 500, 347-350 (2001).
14. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., and Guengerich, F. P., Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270, 414-423 (1994).
15. Shou, M., Mei, Q., Ettore, M. W., Jr., Dai, R., Baillie, T. A., and Rushmore, T. H., Sigmoidal kinetic model for two cooperative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem. J., 340 ( Pt 3), 845-853 (1999).
16. Ueng, Y. F., Kuwabara, T., Chun, Y. J., and Guengerich, F. P., Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry, 36, 370-381 (1997).
17. Venkatakrishnan, K., von Moltke, L. L., Duan, S. X., Fleishaker, J. C., Shader, R. I., and Greenblatt, D. J., Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J. Pharm. Pharmacol., 50, 265-274 (1998).
18. Ward, B. A., Gorski, J. C., Jones, D. R., Hall, S. D., Flockhart, D. A., and Desta, Z., The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther., 306, 287-300 (2003).